Genentech’s Anti-VEGF/Ang2 Bispecific for Retinal Vascular Diseases & a Review of Their Pipeline
Time: 12:00 pm
day: Day One
Details:
- Discussing the benefits of using bispecifics to treat retinal vascular disease
- A case study on the use of Faricimab in retinal vascular disease
- Reviewing Genentech’s current pipeline
